CMS assigns Q codes to procedures, services, and supplies on a temporary basis. When a permanent code is assigned, the Q code is deleted and cross-referenced.
Power pack base for use with electric/pneumatic ventricular assist device, replacement only
Emergency power source for use with electric ventricular assist device, replacement only
Emergency power source for use with electric/pneumatic ventricular assist device, replacement only
Emergency power supply cable for use with electric ventricular assist device, replacement only
Emergency power supply cable for use with electric/pneumatic ventricular assist device, replacement only
Emergency hand pump for use with electric or electric/pneumatic ventricular assist device, replacement only
Battery/power pack charger for use with electric or electric/pneumatic ventricular assist device, replacement only
Battery, other than lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Battery clips for use with electric or electric/pneumatic ventricular assist device, replacement only
Holster for use with electric or electric/pneumatic ventricular assist device, replacement only
Continued
Belt/vest/bag for use to carry external peripheral components of any type ventricular assist device, replacement only
Filters for use with electric or electric/pneumatic ventricular assist device, replacement only
Shower cover for use with electric or electric/pneumatic ventricular assist device, replacement only
Mobility cart for pneumatic ventricular assist device, replacement only
Battery for pneumatic ventricular assist device, replacement only, each
Power adapter for pneumatic ventricular assist device, replacement only, vehicle type
Battery, lithium-ion, for use with electric or electric/pneumatic ventricular assist device, replacement only
Miscellaneous supply or accessory for use with an external ventricular assist device
Miscellaneous supply or accessory for use with an implanted ventricular assist device
Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a
Pharmacy supply fee for initial immunosuppressive drug(s), first month following transplant
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period
Pharmacy dispensing fee for inhalation drug(s); per 30 days
Pharmacy dispensing fee for inhalation drug(s); per 90 days
Injection, sermorelin acetate, 1 microgram
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 30-days
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 60-days
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription drug, per 90-days
New technology intraocular lens category 4 as defined in federal register notice
Continued
New technology intraocular lens category 5 as defined in federal register notice
Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
Injection, fosphenytoin, 50 mg phenytoin equivalent
Injection, teniposide, 50 mg
Injection, radiesse, 0.1 ml
Injection, sculptra, 0.5 mg
Influenza virus vaccine, split virus, for intramuscular use (agriflu)
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
Influenza virus vaccine, not otherwise specified
Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose